Clinical Trial Update: DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. [Phase 2, Phase 3]

View source ↗

Summary

The DETERMINE trial's Arm 07 is studying dabrafenib plus trametinib in patients with BRAF V600 mutation-positive cancers across age groups; the trial is in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Colorectal Cancer
• Erdheim-chester Disease
• Glioma
• Langerhans Cell Histiocytosis
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Papillary Thyroid Carcinoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Cancer Research UK | Conditions: Haematological Malignancy, Malignant Neoplasm | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING